Smoldering Multiple Myeloma – to treat or not to treat?

Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma along the spectrum of clonal plasma cell proliferative disorders. Smoldering multiple myeloma may take years to become active multiple myeloma. In some cases, people who have this condition never develop active multiple myeloma. 

In this episode we have the pleasure of having the Norwegian haematologist Fredrik Schjesvold with us. Fredrik is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. Fredrik is an international expert on Multiple Myeloma in charge of one of Europe’s largest centres for clinical research in this disease. He is also chairman of the Nordic Myeloma Study Group and leads the Norwegian Myeloma Group. Besides he is member of the International Myeloma Working Group, and board member of the European Myeloma network (EMN).

 MAT-BE-2400119  (ver. 1)  02.2024